Intellia Therapeutics (NTLA) Profit After Tax (2015 - 2026)
Intellia Therapeutics (NTLA) reported Profit After Tax of -$96.2 million for Q1 2026, up 15.83% year-over-year from -$83.1 million in Q1 2025, and little changed quarter-over-quarter from -$95.8 million in Q4 2025.
Intellia Therapeutics (NTLA) Profit After Tax (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of Profit After Tax data on file, last reported at -$96.2 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$96.2 million, up 15.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$394.6 million (up 24.97% YoY), and the FY2025 annual result was -$412.7 million, up 20.49% from the prior year.
- Profit After Tax steadied at -$96.2 million in Q1 2026 per NTLA's latest filing, from -$95.8 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$95.8 million in Q4 2025 and troughed at -$147.0 million in Q2 2024.
- A 5-year average of -$116.7 million and a median of -$113.4 million in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax tumbled 217.87% in 2022, then soared 31.11% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$113.4 million in 2022, then dropped by 16.54% to -$132.2 million in 2023, then advanced by 2.47% to -$128.9 million in 2024, then rose by 25.69% to -$95.8 million in 2025, then fell by 0.46% to -$96.2 million in 2026.
- Business Quant data shows NTLA's Profit After Tax at -$96.2 million in Q1 2026, -$95.8 million in Q4 2025, and -$101.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -96.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.23 Mn |
| Dec 31, 2025 | -95.79 Mn |
| Sep 30, 2025 | -101.32 Mn |
| Jun 30, 2025 | -101.26 Mn |
| Mar 31, 2025 | -114.33 Mn |
| Dec 31, 2024 | -128.90 Mn |
| Sep 30, 2024 | -135.71 Mn |
| Jun 30, 2024 | -146.98 Mn |
| Mar 31, 2024 | -107.44 Mn |
| Dec 31, 2023 | -132.16 Mn |
| Sep 30, 2023 | -122.22 Mn |
| Jun 30, 2023 | -123.68 Mn |
| Mar 31, 2023 | -103.13 Mn |
| Dec 31, 2022 | -113.41 Mn |
| Sep 30, 2022 | -113.23 Mn |
| Jun 30, 2022 | -100.68 Mn |
| Mar 31, 2022 | -146.87 Mn |
| Dec 31, 2021 | -81.24 Mn |
| Sep 30, 2021 | -71.64 Mn |
| Jun 30, 2021 | -68.81 Mn |